Provectus Pharma (PVCT) 0.11 $PVCT Provectus

New Post Public Reply Private Reply Replies (0) Message Board

Sep 19, 2016 at 5:11 AM

Provectus Pharma (PVCT) 0.11 $PVCT

Provectus Biopharmaceuticals to Present at Rodman & Renshaw's 18th Annual Global Investment Conference
BusinessWire - Thu Sep 08, 5:00AM CDT
--Conference at Lotte New York Palace Hotel, September 11-13, 2016
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals, Inc. Announces Closing of Public Offering
BusinessWire - Tue Aug 30, 3:01PM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) ("Provectus" or the "Company"

, a clinical-stage oncology and dermatology biopharmaceutical company, today announced that it has completed its public offering of 240,000 shares of Series B Convertible Preferred Stock and warrants to purchase 24,000,000 shares of common stock at a price to the public of $25.00 for a combination of one share of Series B Convertible Preferred Stock and 100 warrants to purchase one share of common stock each. The warrants have an exercise price of $0.275 per share, are exercisable immediately and will expire on August 30, 2021.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals, Inc. Announces Pricing of Public Offering to Raise $6 Million
BusinessWire - Thu Aug 25, 8:25AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.provectusbio.com) ("Provectus" or the "Company"

, a clinical-stage oncology and dermatology biopharmaceutical company, today announced the pricing of a "best efforts" public offering of 240,000 shares of Series B Convertible Preferred Stock (which are initially convertible into an aggregate of 24,000,000 shares of common stock) and warrants initially exercisable to purchase an aggregate of 24,000,000 shares of common stock with a public offering price of $25.00 for a combination of one share of Series B Convertible Preferred Stock and a warrant to purchase one share of common stock. The warrants have an exercise price of $0.275 per share, are exercisable immediately, and will expire on August 30, 2021. The Company expects to receive gross proceeds of approximately $6 million, before deducting placement agent fees and commissions and other estimated offering expenses.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals, Inc. Announces Proposed Public Offering of Preferred Stock and Warrants
BusinessWire - Wed Aug 24, 3:05PM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT

VCT, www.provectusbio.com) ("Provectus" or the "Company"

, a clinical-stage oncology and dermatology biopharmaceutical company, today announced that it intends to offer and sell shares of its Series B Convertible Preferred Stock and warrants to purchase common stock, subject to market and other conditions, in a "best efforts" public offering. Provectus intends to use the net proceeds of the offering for clinical development, working capital and general corporate purposes.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals, Inc. Receives Patent from USPTO Related to Rose Bengal Analogs
BusinessWire - Tue Aug 23, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT

VCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"

today announced that it has received a U.S. patent covering additional aspects of its process for synthesizing halogenated xanthenes, the family of compound to which rose bengal belongs. The patent covers use of certain halogenated xanthenes in pharmaceutical compositions and as medicaments.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results
BusinessWire - Tue Aug 09, 4:05PM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT

VCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"

today announced its financial results for the quarter ended June 30, 2016.
PVCT: 0.11 (+0.01)

Investor Calendar Invites You to the Provectus Biopharmaceuticals Second Quarter 2016 Earnings Conference Call and Webcast Live on Wednesday, August 10, 2016
ACCESSWIRE - Tue Aug 09, 3:11PM CDT
KNOXVILLE, TN / ACCESSWIRE / August 9, 2016 / Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) will host a live conference call and webcast to discuss the results of the second quarter 2016, to be held Wednesday, August 10, 2016 at 4:00 PM Eastern Time.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 for Melanoma at European Society for Medical Oncology 2016 Congress
BusinessWire - Mon Aug 01, 5:00AM CDT
--Congress Scheduled to Run October 7-11, 2016, Copenhagen, Denmark
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 at Annual Meeting of American Society of Clinical Oncology Now Available Online
BusinessWire - Thu Jun 09, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company"

, today announced that the poster presented at the Annual Meeting of the American Society of Clinical Oncology is now available online.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Announces Publication of Article on PV-10 for In-Transit Melanoma in Journal of Surgical Oncology
BusinessWire - Tue Jun 07, 3:00PM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT

VCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company"

, today announced that an article on the use of PV-10 for in-transit melanoma has been published by the Journal of Surgical Oncology. It expands on a presentation on the same topic given at the Royal Australasian College of Surgeons 85th Annual Scientific Congress, which was held 2-6 May 2016, in Brisbane, Australia.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Will Present at 2016 BIO International Convention in San Francisco, CA
BusinessWire - Tue Jun 07, 5:00AM CDT
--BIO International Convention Runs June 6-9, 2016
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Launches Newly Redesigned Website and Official Facebook Page
BusinessWire - Wed Jun 01, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT

VCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company"

, announced today the launch of its newly redesigned website at www.Provectusbio.com as well as the company's official Facebook page at www.facebook.com/Provectusbio.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Announces Abstract Available on PV-10 Plus Radiotherapy in Melanoma
BusinessWire - Thu May 19, 3:00PM CDT
--ASCO Meeting Runs June 3-7, 2016, Chicago, Illinois
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Announces Abstract Available Online of Trials in Progress; Abstract for Poster Presentation at ASCO Annual Meeting
BusinessWire - Thu May 19, 5:00AM CDT
--ASCO Meeting Runs June 3-7, 2016, Chicago, Illinois
PVCT: 0.11 (+0.01)

StockNewsNow.com Publishes May 2016 Update SNNLive Video Interview with Provectus Biopharmaceuticals, Inc.
PR Newswire - Tue May 17, 6:55AM CDT
StockNewsNow.com, The Official MicroCap News Source(TM), today published an SNNLive Video Interview with Peter R. Culpepper, Interim CEO and COO of Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT), specializes in developing oncology and dermatology therapies, according to the company's website (see here: www.ProvectusBio.com). The video interview was recorded on Wednesday, May 4th, 2016, at the Growth Capital Expo MicroCap Investor Conference in Las Vegas, NV.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Announces Publication of Article in Oncotarget Detailing PV-10's Immuno-Ablative Mechanism of Action
BusinessWire - Fri May 13, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT

VCT, www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company"

, today announced that an article has been published detailing the immuno-ablative mechanism of action of PV-10, the Company's novel investigational drug for cancer.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals, Inc. Reports First Quarter 2016 Financial Results
BusinessWire - Tue May 10, 5:12PM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT

VCT) (www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"

, today announced its financial results for the first quarter 2016 ended March 31, 2016.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Will Hold Its 2016 First Quarter Business Update Conference Call on Tuesday, May 10, 2016, at 4 pm Eastern Daylight Time
BusinessWire - Wed May 04, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"

, announced today that it will host its 2016 first quarter business update conference call on Tuesday, May 10, 2016 at 4 pm Eastern Daylight Time.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Announces Publication of Two Abstracts on Research into IL PV-10 for Melanoma in Special Issue of ANZ Journal of Surgery
BusinessWire - Thu Apr 28, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT

VCT, www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company"

, announced today that two abstracts related to research into IL PV-10 for treatment for melanoma have been published in a special issue of the ANZ Journal of Surgery detailing the Royal Australasian College of Surgeons 85th Annual Scientific Congress, 2-6 May 2016, in Queensland, Australia.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals to Participate in Panel at Third International Conference on the Progress of Regenerative Medicine and Its Cultural Impact
BusinessWire - Wed Apr 27, 5:00AM CDT
--Conference Runs April 28-30, 2016, in Vatican City
PVCT: 0.11 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EnGenius Names Experienced VP to Boost Sales Growth

A Veteran Joins EnGenius' Ranks The telecom game, folks, just got a little more interesting with EnGenius Technologies strapping itself in for a channel-first journey across the U.S. and Canada. They've placed a seasoned player, Rachel Saunders, into the cockpit as Vice President of Sales, North America. Her resume reads like a telecom scout's dream: 17 years in electric...

Celebrating Appalachian Soul with Aristotle Jones

Igniting a Celebration of Appalachian Soul Now here's a sound that hits you right in the gut. Aristotle Jones, known out there as the 'Appalachian Soul Man,' is making a big move. He's laying out the plan to make July the Appalachian Soul Month. This fellow isn't shy about celebrating the deep roots of Appalachian music, dropping his album Appalachian Soul Power and a new...

Omneky Integrates AI Growth Agent With Slack for Ads

Omneky's New Move: AI Growth Agent Meets Slack Picture this: You've got a marketing team hustling in the digital age, and now they've got a new ally. Omneky, the big-wig in autonomous AI growth, has snuck its AI Growth Agent right into Slack. This isn't just a party trick during Dreamforce week in San Francisco. This is Omneky throwing another cog into the advertising...

Metriport Eyes Major Step in Health Data Integration

Metriport's Push into the TEFCA Framework Son of a gun, Metriport's making noise in the health data world! They just got the nod as a Candidate QHIN under the Trusted Exchange Framework and Common Agreement, or TEFCA if you're into acronyms. This isn't just some digital high-five; it's a significant stride forward for healthcare data exchange. Now they're smack in the...

Airswift's Strategic Acquisition Boosts U.S. Energy Presence

What's Driving Airswift's Latest Expansion? Airswift just dropped a bombshell by snapping up key businesses from New Tech Global (NTG), marking a serious power move in the U.S. energy sector. Now, what does this actually mean for investors? In blunt terms: they're muscling up their contractor base by a meaty 30%. That's no small feat. It's a calculated step to ace the...

Piedmont Orthopedics Expands Care in Henry County

A Surgeon's Story Comes to Henry County Ah, the medical field. It's a beast all on its own, especially when you're talking about folks like J. Hunter Matthews, M.D. making waves in the orthopedic world. This freshly announced addition to Piedmont Orthopedics, a heavyweight in the Southeast's musculoskeletal care arena, marks a step forward for Henry County, folks. We're...

Foodcare Proves Effective in Reducing Blood Sugar Levels

A New Chapter for Diabetes Care: Foodcare Folks, we've got ourselves a game-changer in the world of diabetes care. Listen closely: Foodsmart's latest study, hot off the press from the American Heart Association's Circulation, essentially hands over the blueprint for tackling type 2 diabetes in an innovative fashion. Now, I'm not the type to get all mushy over scientific...

Andover Audio's FreePlay: Stereo Sound Goes Portable

If there's one thing I've seen grow in leaps and bounds, it's the audio world. Andover Audio’s latest move? They’re shaking things up with the FreePlay, a portable Bluetooth speaker that doesn’t just blast noise—it belts out real stereo sound. Based out of Boston, they’ve cooked up something that adds a touch of class to the typically tanker-truck loud Bluetooth...

Bud Ecosystem Debuts AIOS, Aims to Slash Costs

AI Fragmentation Tax: Cut It Out! Look, if you think AI is all about fancy algorithms and self-learning voodoo, you're missing the plot. It's the nuts and bolts—the infrastructure—that's been bleeding enterprises dry. That's where Bud Ecosystem comes thrashing in with its Novaria AIOS. They're not just promising a tiny tune-up; they're talking slashing AI costs by a...

EmpowHer Grants Propel Female-led Social Ventures Forward

Every now and then, you stumble upon a story that makes you take off your trading hat and put on your 'citizen of the world' one. The Boundless Futures Foundation is doing just that, pushing past the $1.5 million mark in grant funding to back female founders creating real scale impact. If this doesn't sound like a nonprofit turning the gears of change, I don't know what...